Zobrazeno 1 - 10
of 309
pro vyhledávání: '"Jan H Beumer"'
Autor:
Dae-Hee Lee, Ying Zhang, Amin B Kassam, Myung-Jin Park, Paul Gardner, Daniel Prevedello, Stephanie Henry, Craig Horbinski, Jan H Beumer, Hussein Tawbi, Brian J Williams, Mark E Shaffrey, Merrill J Egorin, Roger Abounader, Deric M Park
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134426 (2015)
The majority of chordomas show activation of the platelet-derived growth factor receptor (PDGFR). Based on in vitro intertumoral variation in response to recombinant PDGF protein and PDGFR inhibition, and variable tumor response to imatinib, we hypot
Externí odkaz:
https://doaj.org/article/b9e40afa3cfc436788788ef2f5fd5a4d
Autor:
Frank P. Vendetti, Pinakin Pandya, David A. Clump, Sandra Schamus-Haynes, Meysam Tavakoli, Maria diMayorca, Naveed M. Islam, Jina Chang, Greg M. Delgoffe, Jan H. Beumer, Christopher J. Bakkenist
Publikováno v:
JCI Insight, Vol 8, Iss 4 (2023)
Inhibitors of the DNA damage signaling kinase ATR increase tumor cell killing by chemotherapies that target DNA replication forks but also kill rapidly proliferating immune cells including activated T cells. Nevertheless, ATR inhibitor (ATRi) and rad
Externí odkaz:
https://doaj.org/article/2f7f9a5a81154266a062c203c4294115
Autor:
Jonathan B. Mandell, Nerone Douglas, Vrutika Ukani, Jan H. Beumer, Jianxia Guo, John Payne, Rebecca Newman, Luigi Mancinelli, Giuseppe Intini, Carolyn J. Anderson, Rebecca Watters, Kurt Weiss
Publikováno v:
Sarcoma, Vol 2022 (2022)
Aldehyde dehydrogenase 1A1 (ALDH) is a cancer stem cell marker highly expressed in metastatic cells. Disulfiram (Dis) is an FDA-approved antialcoholism drug that inhibits ALDH and has been studied as a candidate for drug repurposing in multiple neopl
Externí odkaz:
https://doaj.org/article/5610d5455df849079aaab8917461d7fa
Ethics and Clinical Research: Improving Transparency and Informed Consent in Phase I Oncology Trials
Autor:
Paul H. Frankel, Susan Groshen, Jan H. Beumer, Laura Cleveland, Edward S. Kim, Judith E. Karp
Publikováno v:
Journal of Clinical Oncology. 41:2155-2158
Autor:
Monica K. Malhotra, Shalu Pahuja, Brian F. Kiesel, Leonard J. Appleman, Fei Ding, Yan Lin, Hussein A. Tawbi, Ronald G. Stoller, James J. Lee, Chandra P. Belani, Alice P. Chen, Vincent L. Giranda, Stacie Peacock Shepherd, Leisha A. Emens, S. Percy Ivy, Edward Chu, Jan H. Beumer, Shannon Puhalla
Publikováno v:
Breast Cancer Research and Treatment. 198:487-498
Autor:
Jan H. Beumer, Benjamin C. Kennard, Julianne L. Holleran, Nancy Moore, Jennifer Zlott, Brian M. Miller, Shivaani Kummar, Alice Chen, James Doroshow, Wansu Park, Jogarao Gobburu, Allison Dunn
Publikováno v:
Cancer Chemotherapy and Pharmacology. 91:219-230
Autor:
Maura K. McCall, Susan M. Sereika, Stephanie Snader, Alexa Lavanchy, Margaret Q. Rosenzweig, Yvette P. Conley, Jan H. Beumer, Catherine M. Bender
Publikováno v:
Supportive Care in Cancer. 30:9329-9340
Autor:
Feyisola P. Olatunji, Michael Pun, Jacob W. Herman, Oscar Romero, Mitchell Maniatopoulos, Joseph D. Latoche, Robert A. Parise, Jianxia Guo, Jan H. Beumer, Carolyn J. Anderson, Clifford E. Berkman
Publikováno v:
Mol Cancer Ther
New targeted chemotherapeutics are urgently needed to minimize off-target toxicity and reduce the high-mortality rate associated with metastatic prostate cancer. Herein, we report on the modular synthesis, pharmacokinetics, and efficacy of two small-
Autor:
Thomas Cash, Hunter C. Jonus, Maya Tsvetkova, Jan H. Beumer, Arhanti Sadanand, Jasmine Y. Lee, Curtis J. Henry, Dolly Aguilera, R. Donald Harvey, Kelly C. Goldsmith
Publikováno v:
Pediatric Blood & Cancer.
Autor:
Brian F. Kiesel, Joshua J. Deppas, Jianxia Guo, Robert. A. Parise, David A. Clump, Christopher J. Bakkenist, Jan H. Beumer
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: Ataxia Telangiectasia and Rad3-related (ATR) is a pivotal component of the DNA damage response and repair pathways that is activated in responses to cytotoxic cancer treatments. Several ATR inhibitors (ATRi) are in development that block the